Abstract

Cervical cancer, primarily caused by persistent high-risk human papillomavirus (HPV) infection, is a significant global health concern affecting women worldwide. This article delves into the intricate relationship between genetics and cervical cancer, exploring the role of genetic factors in susceptibility, tumor development, and personalized treatment strategies. The genetic landscape of cervical cancer encompasses host genetic variations that influence susceptibility to HPV infection, alterations in tumor suppressor genes and oncogenic pathways that drive abnormal cell growth, and epigenetic modifications that silence critical genes. Moreover, hereditary factors and rare genetic syndromes contribute to a subset of cases. The emergence of precision medicine has paved the way for personalized treatment approaches that target genetic alterations in cervical cancer cells, thereby improving treatment efficacy. Although genetic testing is not the primary method for cervical cancer screening, it holds potential for identifying individuals at elevated risk due to genetic predisposition. Regular screening, HPV vaccination, and genetic counseling collectively contribute to early detection, prevention, and informed decision-making. As we unravel the genetic tapestry of cervical cancer, we gain profound insights into its complexities, paving the way for a future with improved management and reduced disease burden.